Agent for treatment of PBC
The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.
1. A method for the treatment of primary biliary cirrhosis, comprising administering (R)-2-[3-[[N-(benzoxazole-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof to a patient in need thereof.
2. The method for the treatment of primary biliary cirrhosis according to claim 1 , further comprising administering ursodeoxycholic acid.
3. The method for the treatment of primary biliary cirrhosis according to claim 1 , wherein the (R)-2-[3-[[N-(benzoxazole-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof is administered to the patient in a daily dose of 0.05 to 0.8 mg.
4. The method for the treatment of primary biliary cirrhosis according to claim 1 , wherein the administering decreases the level of total bilirubin in the patient.
5. The method for the treatment of primary biliary cirrhosis according to claim 4 , wherein the decrease in the level of total bilirubin in the patient is a decrease of 10% to 75% compared to the level before administration.